Paclitaxel (Taxol) and taxoid derivates for lung cancer treatment: Potential for aerosol delivery

Current Cancer Drug Targets

Volumn 3, Issue 4, 2003, Pages 287-296

  Gautam, Ajay ^a   Koshkina, Nadezhda ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; COPOLYMER; CREMOPHOR; DILAUROYLPHOSPHATIDYLCHOLINE; DOCETAXEL; EPIRUBICIN; EPIRUBICINOL; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; INTERLEUKIN 12; INTERLEUKIN 8; IRINOTECAN; MACROGOL; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; POLYMER; PROTEIN P16; PROTEIN P21; PROTEIN P53; TAXOID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

AEROSOL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG ADMINISTRATION ROUTE; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INTERMETHOD COMPARISON; LUNG CANCER; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; PACLITAXEL;

EID: 0042129873     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009033481912     Document Type: Review

References (62)

1. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. Plant Antitumor Agents. VI. The Isolation and Structure of PTX, a Novel Antileukemic And Antitumor Agent From Taxus Brevifolia. J. Am. Chem. Soc. 1971, 93, 2325-7.
2. Schiff, P. B.; Fant, J.; Horwitz, S. B. Promotion of Microtubule Assembly in Vitro by PTX. Nature 1979, 277, 665-667.
3. McGuire, W. P.; Rowinsky, E. K.; Rosenshein, N. B.; Grumbine, F. C.; Ettinger, D. S.; Armstrong, D. K.; Donehower, R. C. PTX: a Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial Neoplasms. Ann. Intern. Med. 1989, 111, 273-9.
4. Miller, M. L.; Ojima, I. Chemistry and Chemical Biology Of Taxane Anticancer Agents. Chem. Rec. 2001, 1,195-211.
5. Ounatilaka, A. A.; Ramdayal, F. D.; Sarragiotto, M. H.; Kingston, D. G.; Sackett, D. L.; Hamel, E. Synthesis and Biological Evaluation of Novel Paclitaxel (PTX) D-Ring Modified Analogues. J. Org. Chem. 1999, 64, 2694-2703.
6. Ojima, I.; Wang, T.; Miller, M. L.; Lin, S.; Borella, C. P.; Geng, X.; Pera, P.; Bernacki, R. J. Synthesis and Structure-Activity Relationships of New Second-Generation Taxoids. Bioorg. Med. Chem. Lett. 1999, 9, 3423-8.
7. Wang, M.; Cornett, B.; Nettles, J.; Liotta, D. C.; Snyder, J. P. The Oxetane Ring in PTX. J. Org. Chem. 2000, 65,1059-68.
8. Gueritte-Voegelein, F.; Guenard, D.; Lavelle, F.; Le Goff, M. T.; Mangatal, L.; Potier, P. Relationships between the Structure of PTX Analogues and their antimitotic Activity. J. Med. Chem. 1991, 34, 992-8.
9. Swindell, C. S.; Krauss, N. E.; Horwitz, S. B.; Ringel, I. Biologically Active PTX Analogues with Deleted A-Ring Side Chain Substituents and Variable C-2′ Configurations. J. Med. Chem. 1991, 34, 1176-84.
10. Fukushima, M.; Fukamiya, N.; Okano, M.; Nehira, T.; Tagahara, K.; Zhang, S. X.; Zhang, D. C.; Tachibana, Y.; Bastow, K. F.; Lee, K. H. Cytotoxity of Non-Alkaloidal Taxane Diterpenes from Taxus chinensis against a Paclitaxel-Resistant Cell Line. Cancer Lett. 2000, 158, 151-4.
11. Ojima, I.; Slater, J. C.; Kuduk, S. D.; Takeuchi, C. S.; Gimi, R. H.; Sun, C. M.; Park, Y. H.; Pera, P.; Veith, J. M.; Bernacki, R. J. Syntheses and Structure-Activity Relationships of Taxoids Derived from 14 Beta-Hydroxy-10-Deacetylbaccatin III. J. Med. Chem. 1997, 40, 267-78.
12. Bissery, M. C.; Guenard, D.; Gueritte-Voegelein, F.; Lavelle, F. Experimental Antitumor Activity of Taxotere (RP 56976, NSC 628503), a PTX Analogue. Cancer Res. 1991, 51, 4845-4852.
13. Shtil, A. A.; Mandlekar, S.; Yu, R.; Walter, R. J.; Hagen, K.; Tan, T. H.; Roninson, I. B.; Kong, A. N. Differential Regulation of Mitogen-Activated Protein Kinases by Microtubule-Binding Agents in Human Breast Cancer Cells. Oncogene 1999, 18, 377-384.
14. Collins, T. S.; Lee, L. F.; Ting, J. P. Paclitaxel Up-Regulates Interleukin-8 Synthesis in Human Lung Carcinoma through an NF-kappaB- and AP-1-Dependent Mechanism. Cancer Immunol. Immunother. 2000, 49,78-84.
15. Bacus, S. S.; Gudkov, A. V.; Lowe, M.; Lyass, L.; Yung, Y.; Komarov, A. P.; Keyomarsi, K.; Yarden, Y.; Seger, R. PTX-Induced Apoptosis Depends on MAP Kinase Pathways (ERK and p38) and is Independent of p53. Oncogene 2001, 20,147-155.
16. Gadducci, A.; Cosio, S.; Muraca, S.; Genazzani, A. R. Molecular Mechanisms of Apoptosis and Chemosensitivity to Platinum and Paclitaxel in Ovarian Cancer: Biological Data and Clinical Implications. Eur. J. Gynaecol. Oncol. 2002, 23, 390-396.
17. Safran, H.; King, T.; Choy, H.; Gollerkeri, A.; Kwakwa, H.; Lopez, F.; Cole, B.; Myers, J.; Tarpey, J.; Rosmarin, A. p53 Mutations Do Not Predict Responseto Paclitaxel/Radiation for Nonsmall Cell Lung Carcinoma. Cancer 1996, 78,1203-10.
18. Kalechman, Y.; Shani, A.; Dovrat, S.; Whisnant, J. K.; Mettinger, K.; Albeck, M.; Sredni, B. The Antitumoral Effect of The Immunomodulator AS101 and Paclitaxel (PTX)in A Murine Model of Lung Adenocarcinoma. J. Immunol. 1996, 156, 1101-1109.
19. Avramis, V. I.; Nandy, P.; Kwock, R.; Solorzano, M. M.; Mukherjee, S. K.; Danenberg, P.; Cohen, L. J. Increased P21/WAF-1 and P53 Protein Levels Following Sequential Three Drug Combination Regimen of Fludarabine, Cytarabine and Docetaxel Induces Apoptosisin Human Leukemia Cells. Anticancer Res. 1998, 18, 2327-2338.
20. Wang, J.; Lou, P.; Lesniewski, R.; Henkin, J. Paclitaxel At Ultra Low Concentrations Inhibits Angiogenesis Without Affecting Cellular Microtubule Assembly. Anticancer Drugs 2003, 14, 13-19.
21. Herbst, R. S.; Madden, T. L.; Tran, H. T.; Blumenschein, G. R. Jr.; Meyers, C. A.; Seabrooke, L. F.; Khuri, F. R.; Puduvalli, V. K.; Allgood, V.; Fritsche, H. A. Jr.; Hinton, L.; Newman, R. A.; Crane, E. A.; Fossella, F. V.; Dordal, M.; Goodin, T.; Hong, W. K. Safety and Pharmacokinetic Effects of TNP-470, an Angiogenesis Inhibitor, Combined with Paclitaxelin Patients with Solid Tumors: Evidence for Activityin Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2002, 20, 4440-4447.
22. Tan, M; Jing, T.; Lan, K. H.; Neal, C. L.; Li, P.; Lee, S.; Fang, D.; Nagata, Y.; Liu, J.; Arlinghaus, R.; Hung, M. C.; Yu, D. Phosphorylation On Tyrosine-15 of P34(Cdc2) By Erbb2 Inhibits P34(Cdc2) Activation and is Involvedin Resistanceto PTX-Induced Apoptosis. Mol. Cell 2002, 9, 993-1004.
23. Knapp, D. C.; Mata, J. E.; Reddy, M. T.; Devi, G. R.; Iversen, P. L. Resistanceto Chemotherapeutic Drugs Overcome By C-Myc Inhibitionin A Lewis Lung Carcinoma Murine Model. Anticancer Drugs 2003, 14, 39-47.
24. Cesaro, P.; Raiteri, E.; Demoz, M.; Castino, R.; Baccino, F. M.; Bonelli, G.; Isidoro, C. Expression of Protein Kinase C Beta1 Confers Resistanceto Tnfalpha- and Paclitaxel-Induced Apoptosisin HT-29 Colon Carcinoma Cells. Int. J. Cancer 2001, 93, 179-184.
25. Giannakakis, T.; Kakolyris, S.; Theodoropoulos, E.; Kouroussis, C.; Michailakis, E.; Papadouris, S.; Tsitoura, M.; Kalbakis, K.; Souglakos, J.; Agelaki, S.; Vardakis, N.; Georgoulias, V. A Multicenter Phase II Study of Docetaxel and Carboplatin Combination as Front-Line Treatmentin Advanced Non-Small Cell Lung Cancer. Anticancer Res. 2002, 22, 3743-3748.
26. Socinski, M. A.; Sandler, A. B.; Israel, V. K.; Gillenwater, H. H.; Miller, L. L.; Locker, P. K.; Antonellini, A.; Elfring, G. L.; Natale, R. B. Phase II Trial of Irinotecan, Paclitaxel and Carboplatinin Patients with Previously Untreated Stage IIIB/IV Nonsmall Cell Lung Carcinoma. Cancer 2002, 95, 1520-1527.
27. Fogli, S.; Danesi, R.; Gennari, A.; Donati, S.; Conte, P. F.; Del Tacca, M. Gemcitabine, Epirubicin and Paclitaxel: Pharmacokinetic and Pharmacodynamic Interactionsin Advanced Breast Cancer. Ann. Oncol. 2002, 13, 919-927.
28. Nguyen, N. P.; Leonardo, J. M.; Karlsson, U.; Vos, P.; Bullock, L.; Thomas, P.; Lepera, P.; Ludin, A.; Chu, C.; Salehpour, M.; Jendrasiak, G.; Sallah, S. Efficacy of Combined Radiation, Paclitaxel and Carboplatin For Locally Advanced Non-Small Cell Lung Carcinoma. Anticancer Res. 2002, 22, 3429-3435.
29. Willner, J.; Schmidt, M.; Kirschner, J.; Lang, S.; Borgmeier, A.; Huber, R. M.; Flentje, M. Sequential Chemo- and Radiochemotherapy with Weekly Paclitaxel (PTX) and 3D-Conformal Radiotherapy of Stage III Inoperable Non-Small Cell Lung Cancer. Results of A Dose Escalation Study. Lung Cancer 2001, 32, 163-171.
30. Kim, E. S.; Khuri, F. R. Docetaxel and Radiation as Combined-Modality Therapy. Oncology 2002, 16, 97-105.
31. Breathnach, O. S.; Kasturi, V.; Kaye, F.; Herscher, L.; Georgiadis, M. S.; Edison, M.; Schuler, B. S.; Pizzella, P.; Steinberg, S. M.; O'Neil, K.; Johnson, B. E. Phase II Neoadjuvant Trial of Paclitaxel By 96-Hour Continuous Infusion (CIVI) in Combination with Cisplatin Followed By Chest Radiotherapy for Patients with Stage III Non-Small-Cell Lung Cancer. Am. J. Clin. Oncol. 2002, 25, 269-273.
32. Nielsen, L. L.; Lipari, P.; Dell, J.; Gurnani, M.; Hajian, G. Adenovirus-Mediated p53 Gene Therapy and Paclitaxel Have Synergistic Efficacyin Models of Human Head and Neck, Ovarian, Prostate, and Breast Cancer. Clin. Cancer Res. 1998, 4, 835-846.
33. Kieback, D. G.; Fischer, D. C.; Engehausen, D. G.; Sauerbrei, W.; Oehler, M. K.; Tong, X. W.; Aguilar-Cordova, E. Intraperitoneal Adenovirus-Mediated Suicide Gene Therapyin Combination with Either Topotecan or Paclitaxel in Nude Mice with Human Ovarian Cancer. Cancer Gene Ther. 2002, 9, 478-481.
34. Gelderblom, H.; Mross, K.; Ten Tije, A. J.; Behringer, D.; Mielke, S.; Van Zomeren, D. M.; Verweij, J.; Sparreboom, A. Comparative Pharmacokinetics of Unbound Paclitaxel During 1- and 3-Hour Infusions. J. Clin. Oncol. 2002, 20, 574-581.
35. Sato, H.; Wang, Y. M.; Adachi, I.; Horikoshi, I. Pharmacokinetic Study of PTX-Loaded Poly(Lactic-Co-Glycolic Acid) Microspheres Containing Isopropyl Myristate After Targeted Deliveryto The Lungin Mice. Biol. Pharm. Bull. 1996, 19, 1596-1601.
36. Zhang, X.; Burt, H. M.; Mangold, G.; Dexter, D.; Von Hoff, D.; Mayer, L.; Hunter, W. L. Anti-Tumor Efficacy and Biodistribution of Intravenous Polymeric Micellar Paclitaxel. Anticancer Drugs 1997, 8, 696-701.
37. Fonseca, C.; Simoes, S.; Gaspar, R. Paclitaxel-Loaded PLGA Nanoparticles: Preparation, Physicochemical Characterization and in Vitro Anti-Tumoral Activity. J. Control Release 2002, 83, 273-286.
38. Sharma, A.; Straubinger, R. M. Novel Taxol Formulations: Preparation and Characterization of Taxol-Containing Liposomes. Pharm. Res. 1994, 11, 889-896.
39. Marchettini, P.; Stuart, O. A.; Mohamed, F.; Yoo, D.; Sugarbaker, P. H. Docetaxel: Pharmacokinetics and Tissue Levels After Intraperitoneal and Intravenous Administration in a Rat Model. Cancer Chemother. Pharmacol. 2002, 49, 499-503.
40. Fidias, P.; Supko, J.G.; Martins, R.; Boral, A.; Carey, R.; Grossbard, M.; Shapiro, G.; Ostler, P.; Lucca, J.; Johnson, B. E.; Skarin, A.; Lynch, T. J. A Phase II Study of Weekly Paclitaxelin Elderly Patients with Advanced Non-Small Cell Lung Cancer. Clin. Cancer Res. 2001, 7, 3942-9.
41. Greco, F. A.; Thomas, M.; Hainsworth, J. D. One-Hour Paclitaxel Infusions: Review of Safety and Efficacy. Cancer J. Sci. Am. 1999, 5, 179-91.
42. Eiseman, J. L.; Eddington, N. D.; Leslie, J.; Macauley, C.; Sentz, D. L.; Zuhowski, M.; Kujawa, J. M.; Young, D.; Egorin, M. J. Plasma Pharmacokinetics and Tissue Distribution of Paclitaxelin CD2FI Mice. Cancer Chemother. Pharmacol. 1994, 34, 465-471.
43. Gianni, L.; Kearns, C. M.; Giani, A.; Capri, G.; Vigano, L.; Lacatelli, A.; Bonadonna, G.; Egorin, M. J. Nonlinear Pharmacokinetics and Metabolism of Paclitaxel and Its Pharmacokinetic/Pharmacodynamic Relationshipsin Humans. J. Clin. Oncol. 1995, 13, 180-190.
44. Sparreboom, A.; Van Asperen, J.; Mayer, U.; Schinkel, A. H.; Smit, J. W.; Meijer, D. K.; Borst, P.; Nooijen, W. J.; Beijnen, J. H.; Van Tellingen, O. Limited Oral Bioavailability and Active Epithelial Excretion of Paclitaxel (PTX) Caused By P-Glycoproteinin The Intestine. Proc. Natl. Acad. Sci. USA 1997, 94, 2031-5.
45. Van Asperen, J.; Van Tellingen, O.; Van Der Valk, M. A.; Rozenhart, M.; Beijnen, J. H. Enhanced Oral Absorption and Decreased Elimination of Paclitaxelin Mice Cotreated with Cyclosporin A. Clin. Cancer Res. 1998, 4, 2293-2297.
46. Meerum-Terwogt, J. M.; Malingre, M. M.; Beijnen, J. H.; Ten Bokkel Huinink, W. W.; Rosing, H.; Koopman, F. J.; Van Tellingen, O.; Swart, M.; Schellens, J. H. Coadministration of Oral Cyclosporin A Enables Oral Therapy with Paclitaxel. Clin. Cancer Res. 1999, 5, 3379-3384.
47. Malingre, M. M.; Ten Bokkel Huinink, W. W.; Duchin, K.; Schellens, J. H.; Beijnen, J. H. Pharmacokinetics of Oral Cyclosporin A When Co-Administeredto Enhance The Oral Absorption of Paclitaxel. Anticancer Drugs 2001, 12, 591-593.
48. Yusuf, R. Z.; Duan, Z.; Lamendola, D. E.; Penson, R. T.; Seiden, M. V. Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation. Curr. Cancer Drug Targets 2003, 3, 1-19.
49. Thomas, D. A.; Myers, M. A.; Wichert, B.; Schreier, H.; Gonzalez-Rothi, R. J. Acute Effects of Liposome Aerosol Inhalation On Pulmonary Functionin Healthy Human Volunteers. Chest 1991, 99, 1268-1270.
50. Yu, J.; Chien, Y. W. Pulmonary Drug Delivery: Physiologic and Mechanistic Aspects. Crit. Rev. Ther. Drug Carrier Syst. 1997, 14, 395-453.
51. Knight, V.; Kleinerman, E. S.; Waldrep, J. C.; Giovanella, B. C.; Gilbert, B. E.; Koshkina, N. V. 9-Nitrocamptothecin Liposome Aerosol Treatment of Human Cancer Subcutaneous Xenografts and Pulmonary Cancer Metastasesin Mice. Ann. N. Y. Acad. Sci. 2000, 922, 151-163.
52. Hershey, A. E.; Kurzman, I. D.; Forrest, L. J.; Bohling, C. A.; Stonerook, M.; Placke, M. E.; Imondi, A. R.; Vail, D. M. Inhalation Chemotherapy for Macroscopic Primary Or Metastatic Lung Tumors: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as A Model. Clin. Cancer Res. 1999, 5, 2653-2659.
53. Khanna, C.; Hasz, D. E.; Klausner, J. S.; anderson, P. M. Aerosol Delivery of Interleukin 2 Liposomes is Nontoxic and Biologically Effective: Canine Studies. Clin. Cancer Res. 1996, 2, 721-734.
54. Gautam, A.; Waldrep, J. C.; Densmore, C. L.; Koshkina, N.; Melton, S.; Roberts, L.; Gilbert, B.; Knight, V. Growth Inhibition of Established B16-F10 Lung Metastases By Sequential Aerosol Delivery of P53 Gene and 9-Nitrocamptothecin. Gene Ther. 2002, 9, 353-357.
55. Jia, S. F.; Worth, L. L.; Densmore, C. D.; Xu, B.; Duan, X.; Kleinerman, E. S. Aerosol Gene Therapy with PEI-IL-12 Eradicates Established Osteosarcoma Lung Metastases. Clin. Cancer Res. 2003, in Press.
56. Verschraegen, C. F.; Gilbert, B. E.; Huaringa, A. J.; Newman, R.; Harris, N.; Leyva, F. J.; Keus, L.; Campbell, K.; Nelson-Taylor, T.; Knight, V. Feasibility, Phase I, and Pharmacological Study of Aerosolized Liposomal 9-Nitro-20(S)-Camptothecinin Patients with Advanced Malignanciesin The Lungs. Ann. N. Y. Acad. Sci. 2000, 922, 352-354.
57. Anderson, P. M.; Markovic, S. N.; Sloan, J. A.; Clawson, M. L.; Wylam, M.; Arndt, C. A.; Smithson, W. A.; Burch, P.; Gornet, M.; Rahman, E. Aerosol Granulocyte Macrophage-Colony Stimulating Factor: A Low Toxicity, Lung-Specific Biological Therapyin Patients with Lung Metastases. Clin. Cancer Res. 1999, 5, 2316-23.
58. Skubitz, K. M.; anderson, P. M. Inhalational Interleukin-2 Liposomes For Pulmonary Metastases: A Phase I Clinical Trial. Anticancer Drugs 2000, 11, 555-63.
59. Koshkina, N. V.; Waldrep, J. C.; Roberts, L. E.; Golunski, E.; Melton, S.; Knight, V. Paclitaxel Liposome Aerosol Treatment Induces Inhibition of Pulmonary Metastasesin Murine Renal Carcinoma Model. Clin. Cancer Res. 2001, 7, 3258-3262.
60. Britten, C. D.; Baker, S. D.; Denis, L. J.; Johnson, T.; Drengler, R.; Siu, L. L.; Duchin, K.; Kuhn, J.; Rowinsky, E. K. Oral Paclitaxel and Concurrent Cyclosporin A: Targeting Clinically Relevant Systemic Exposureto Paclitaxel. Clin. Cancer Res. 2000, 6, 3459-3468.
61. Mistry, P.; Stewart, A. J.; Dangerfield, W.; Okiji, S.; Liddle, C.; Bootle, D.; Plumb, J. A.; Templeton, D.; Charlton, P.in Vitro andin Vivo Reversal of P-Glycoprotein-Mediated Multidrug Resistance By A Novel Potent Modulator, XR9576. Cancer Res. 2001, 61, 749-58.
62. Van Asperen, J.; Van Tellingen, O.; Sparreboom, A.; Schinkel, A. H.; Borst, P.; Nooijen, W. J.; Beijnen, J. It. Enhanced Oral Bioavailability of Paclitaxelin Mice Treated with The P-Glycoprotein Blocker SDZ PSC 833. Br. J. Cancer 1997, 76, 1181-1183.